About
Single cell technologies for drug discovery
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Team (23)
Andrew Griffiths
Andrew Griffiths, PhD
HiFiBiO Therapeutics
team_member
Aurélien Marabelle
Aurélien Marabelle, MD, PhD
HiFiBiO Therapeutics
team_member
Bradley Bernstein
Bradley Bernstein, MD, PhD
HiFiBiO Therapeutics
team_member
Cheryl Cui
Cheryl Cui, PhD
HiFiBiO Therapeutics
team_member
David Weitz
David Weitz, PhD
HiFiBiO Therapeutics
team_member
Francisco Adrian
Francisco Adrian, PhD
HiFiBiO Therapeutics
team_member
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
328
By Phase
PHASE1: 5
By Status
RECRUITING: 2COMPLETED: 2TERMINATED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05789069Lead Sponsor
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
PHASE1Recruiting
83 participants
Started: May 9, 2023 · Completed: Dec 31, 2025
NCT05229601Lead Sponsor
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
PHASE1Terminated
31 participants
Started: Apr 20, 2022 · Completed: May 30, 2024
NCT05238883Lead Sponsor
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
PHASE1Recruiting
170 participants
Started: Mar 10, 2022 · Completed: Dec 31, 2026
NCT05275660Lead Sponsor
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults
PHASE1Completed
20 participants
Started: May 9, 2021 · Completed: Feb 22, 2022
NCT04590430Lead Sponsor
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
PHASE1Completed
24 participants
Started: Oct 20, 2020 · Completed: Jul 26, 2021
Locations (1)
Headquarters
Paris, France
Map
Loading map...